<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180450</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-IMIMH-04</org_study_id>
    <nct_id>NCT03180450</nct_id>
  </id_info>
  <brief_title>The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)</brief_title>
  <official_title>The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study is to evaluate the safety and efficacy of human umbilical cord&#xD;
      mesenchymal stem cells (hUC-MSC) in treating heart failure patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, paralleled study. Patients will be divided into two groups of treatment&#xD;
      and control. all of them will receive conventional treatment based on specific condition,&#xD;
      including digitalis, milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme&#xD;
      Inhibitors (ACEI), angiotension receptor blocker (ARB), and antiplatelet aggregation etc.&#xD;
      Treatment group patients will receive hUC-MSC. Follow-up visit will occur on 3 months, 6&#xD;
      months, and 12 months after the cell transfusion. Vital signs, blood routine test, urine&#xD;
      routine test, liver function examination, etc, will be placed to evaluate the safety of&#xD;
      hUC-MSC treatment. And the change of symptoms to evaluate the efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Others&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart color ultrasound evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Criteria:&#xD;
Excellent: ejection fraction improve to &gt; 50%;&#xD;
Efficient: ejection fraction improved;&#xD;
Inefficient: ejection fraction same as before treatment;&#xD;
Exacerbation: ejection fraction declined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single therapy effectiveness evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate criteria:&#xD;
Recovery: symptoms disappear&#xD;
Excellent: symptoms improved obviously&#xD;
Efficient: symptoms improved&#xD;
Inefficient: symptoms no change or worse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)</intervention_name>
    <description>Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional treatment</intervention_name>
    <description>The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  volunteer to participate in clinical trial, and sign informed consent form&#xD;
&#xD;
          -  with cardiac failure symptoms, including oppression in chest, breathe hard, lower limb&#xD;
             edema. And new york heart association class as two to four&#xD;
&#xD;
          -  heart color ultrasound indicate left ventricular ejection fraction (LVEF) &lt; 40%&#xD;
&#xD;
          -  content of serum NT-proBNP &gt; 450pg/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with severe drug allergy history or allergic constitution&#xD;
&#xD;
          -  patients were severe infected&#xD;
&#xD;
          -  with malignant tumor or with high tumor marker&#xD;
&#xD;
          -  with severe cardiorespiratory dysfunction, hematological system disease&#xD;
&#xD;
          -  with severe mental disorder, cognitive impairment&#xD;
&#xD;
          -  with persistent atrial fibrillation, valvular heart disease, dilated cardiomyopathy,&#xD;
             hypertrophic cardiomyopathy or restrictive cardiomyopathy patients&#xD;
&#xD;
          -  end-stage renal insufficiency, pregnancy, or breast feeding women&#xD;
&#xD;
          -  bleeding tendency, active gastrointestinal ulcer&#xD;
&#xD;
          -  recent have major surgery, stroke, cancer, hepatic function insufficiency or other&#xD;
             life-threatening condition.&#xD;
&#xD;
          -  under other therapy that possibly influence MSC security or efficacy&#xD;
&#xD;
          -  donor: HIV, active hepatitis B/C infection, Syphilitic antibody positive&#xD;
&#xD;
          -  participant/donor: alcoholism, drug addicted, mental disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nashundalai</last_name>
    <role>Study Director</role>
    <affiliation>Inner Mongolia International Mongolian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Guo, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>China-Japan Union Hospital, Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inner Mongolia International Mongolian Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Human Umbilical Cord Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

